Metrics as of 10/15/2026, 02:47 PM (Berlin time), refresh in progress.
Syndax Pharmaceuticals Stock
Syndax Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael A. Metzger
- Employees
- 298
- Market cap
- $1.2 B
- IPO
- 02/03/2016
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm based in the United States that focuses on developing innovative therapies for cancer. The company maintains its corporate headquarters in Waltham, Massachusetts, and is led by CEO Michael A. Metzger. Among its leading investigational products is…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Syndax Pharmaceuticals stock: price history
1D
-3.0%
1W
-20.6%
1M
-26.3%
6M
-44.4%
YTD
-35.6%
1Y
-11.6%
2Y
-31.7%
5Y
-27.2%
10Y
-5.3%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~2% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Syndax Pharmaceuticals
Analyst assessment of Syndax Pharmaceuticals
PRICE TARGET LOW
US$31.00
CONSENSUS
US$36.67
MEDIAN
US$36.00
PRICE TARGET HIGH
US$46.00
0
STRONG BUY
20
BUY
2
HOLD
0
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 13/10/2026
Syndax Pharmaceuticals stock metrics
P/E
-5.37
P/B
79.74
EV/EBITDA
-10.8
RETURN ON EQUITY
-326.9%
NET MARGIN
-67.8%
DEBT/EQUITY
39.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.9%
FLOAT SHARES
80,295,047
AVG. DAILY VOLUME (30D)
2,024,874
Insider transactions (SEC)
Metzger Michael A
Metzger Michael A
Botwood Nicholas A.J.
Botwood Nicholas A.J.
Botwood Nicholas A.J.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Syndax Pharmaceuticals stock
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael A. Metzger, the company employs around 298 people.
The IPO was on 02/03/2016; the stock trades on NASDAQ under the ticker SNDX.
What do analysts say about Syndax Pharmaceuticals stock?
22 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$36.67, ranging from US$31.00 to US$46.00, with a median of US$36.00.
This is an external assessment, not a statement by Market Jury.
When does Syndax Pharmaceuticals report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly -2% stronger than usual.
Does Syndax Pharmaceuticals pay a dividend?
No, Syndax Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Syndax Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Syndax Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Syndax Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.